ImmunityBio Announces ISAF Of Macau Special Administrative Region Of People's Republic Of China Grants Regulatory Approval For ANKTIVA

ImmunityBio, Inc. announced that the Pharmaceutical Administration Bureau of Macau has granted regulatory approval for ANKTIVA (nogapendekin alfa inbakicept-pmln) for patients with BCG-unresponsive non-muscle invasive bladder cancer. This marks the first authorization of ANKTIVA in Asia and supports the company's global expansion strategy across 34 countries. The approval was based on a reliance review referencing prior decisions by the FDA and EMA.